Lifecore Biomedical, Inc. (NASDAQ: LFCR) related to its sale to affiliates of Webster Equity Partners. Under the terms of the proposed transaction, Lifecore shareholders are expected to receive $6.28 in cash per share, plus one non-transferable contingent value right per share, entitling holders to potential additional cash payments based on the Company’s achievement of specified revenue and EBITDA milestones through 2030.